Website Sitemap

Publications

• Expert guidance on when to screen, monitor, and initiate complement inhibition therapy in patients without classical PNH (August 12, 2026)
• Real-world outcomes among Medicare beneficiaries treated with Bruton tyrosine kinase inhibitors for treatment-naive CLL (August 11, 2026)
• Clinical and economic impact on people with relapsing-remitting multiple sclerosis in the United States: a matched-cohort study (August 3, 2026)
• Treatment Patterns of Ocrelizumab Subcutaneous: An Early Look Into Utilization in a Medicare Population With Multiple Sclerosis (June 2, 2026)
• High- or Moderate-Efficacy Treatment Sequence and Patterns Among People with Relapsing-Remitting Multiple Sclerosis in the United States: A Retrospective Cohort Study (May 30, 2026)
• Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) (May 20, 2026)
• Geographic Disparities in Influenza Vaccination Among Medicare and Medicaid Beneficiaries: A National Analysis (May 13, 2026)
• Healthcare Costs Associated With Lyme Disease Among Medicare Fee-for-Service Beneficiaries in the United States: A Retrospective Claims-Based Study (May 13, 2026)
• Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-Controlled Case Series Analysis (May 13, 2026)
• Expert Consensus on Treatment Guidance for FDA-Approved and Second-Generation Exon-Skipping Therapies in Duchenne Muscular Dystrophy (DMD): a RAND/UCLA Modified Delphi Panel (May 13, 2026)
• An AI-Driven Random Survival Forest Model for Predicting Cancer-Specific Survival in Pediatric Neuroblastoma: A SEER Analysis (May 13, 2026)
• Understanding Drug Spend Patterns Among Non-Low Income (NLIS) MAPD Plan Switchers (April 30, 2026)
• Clinical and Economic Impact and Treatment Patterns in People with Secondary Progressive Multiple Sclerosis: A Retrospective Cohort Study in the United States (April 18, 2026)
• A Retrospective Cohort Study to Assess the Clinical and Economic Burden in Treated versus Untreated People with Relapsing-Remitting Multiple Sclerosis in the United States (April 18, 2026)
• Analysis of 340B modifier usage in Medicare Part D claims for IPAY 2026 and IPAY 2027 selected drugs (April 14, 2026)
• Real-world patterns of maintenance therapy after allogeneic transplant in older adults with acute myeloid leukemia: A Medicare cohort study (March 30, 2026)
• Systematic Literature Review on the Effect of Cenegermin on Corneal Sensation and Innervation in Patients with Neurotrophic Keratopathy (March 19, 2026)
• Expert Consensus on Dystrophin and Creatine Kinase as Predictors of Clinical Benefit in Duchenne Muscular Dystrophy: a RAND/UCLA Modified Delphi Panel (March 6, 2026)
• Breaking Barriers to CGT Commercialization: Key Themes from the Inaugural Cell Therapy Commercialization Symposium (February 26, 2026)
• Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone-Sensitive Prostate Cancer (February 18, 2026)
• Understanding Patient Demographics, Clinical Characteristics, Economic Outcomes and Treatment Patterns in People with Nonrelapsing Secondary Progressive Multiple Sclerosis: A Retrospective Cohort Study in the United States (February 3, 2026)
• A Retrospective Cohort Study to Assess the Patient Characteristics, Clinical and Economic Outcomes and Treatment Patterns in People with Primary Progressive Multiple Sclerosis in the United States (February 3, 2026)
• Operationalizing Access for Chimeric Antigen Receptor T cell Therapies: A Cross-functional Perspective (January 8, 2026)
• Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-Controlled Case Series Analysis (November 17, 2025)
• Expert Consensus on the Likelihood and Treatment of Inflammatory and Fibrotic Immunoglobulin A Nephropathy (IgAN) (November 10, 2025)
• Health Outcomes and Survival Among Patients with Severe Hypertriglyceridemia After Acute Pancreatitis (November 4, 2025)
• Effectiveness of teriflunomide in patients with relapsing multiple sclerosis who switched from other disease-modifying therapies (October 22, 2025)
• Expert Consensus Definition of Treatment Intolerance in Chronic Myeloid Leukemia in Chronic Phase (October 9, 2025)
• Corticosteroid (CS) use and risk of adverse events (AEs) in patients (pts) treated for metastatic hormone-sensitive prostate cancer (mHSPC)  (October 3, 2025)
• Comparison of utilization and total medicare fee-for-serviceexpenditures for subcutaneous versus intravenous versions of a selectgroup of therapies (September 12, 2025)
• A Retrospective Matched-Cohort Study to Assess the Clinical and Economic Burden in People with Secondary Progressive Multiple Sclerosis in the United States (September 10, 2025)
• Dosing patterns, healthcare resource utilization and costs among acromegaly patients who consistently use lanreotide and injectable octreotide (July 18, 2025)
• Adherence, duration and healthcare costs in a real-world population of patients with acromegaly (July 8, 2025)
• Clinical and economic burden among older adults with acromegaly in the United States (July 8, 2025)
• Healthcare utilization and costs among patients with acromegaly in the United States (July 8, 2025)
• Real-world use of risdiplam for the treatment of SMA in infants under two months of age (June 27, 2025)
• Disparities in Respiratory Syncytial Virus Vaccine Uptake in the Medicare Fee-For-Service Population During 2023-2024 Season (June 27, 2025)
• Real-world use of risdiplam for the treatment of SMA in infants under two months of age (June 25, 2025)
• Understanding Predictors of Early-Onset Colorectal Cancer in Personal Health Data with Machine Learning (May 13, 2025)
• Disparities in Testing for Deficient Mismatch Repair Genes Among Medicare Beneficiaries With Colon Cancer in the United States: a claims-based analysis. (May 13, 2025)
• Osilodrostat Treatment of Cushing Syndrome in Real-WorldClinical Practice: Findings From the ILLUSTRATE study (May 7, 2025)
• Implications of IRA on Post-Approval Research - Oncology (May 2, 2025)
• Implications of the Inflation Reduction Act Price Setting Provisions on Post-approval New Uses for Biologics (March 17, 2025)
• Understanding the Burden of Illness in People with Primary Progressive Multiple Sclerosis in the United States: A Matched-Cohort Study (February 27, 2025)
• Healthcare Resource Utilization and Economic Burden of Prurigo Nodularis in the United States (February 12, 2025)
• Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study (January 21, 2025)
• A descriptive survey of patient experiences and access to specialty medicines with alternative funding programs (November 30, 2024)
• Development and validation of clinical criteria to identify familialchylomicronemia syndrome (FCS) in North America (November 14, 2024)
• Consensus guidance for management of nausea/vomiting in patients treated with zolbetuximab + chemotherapy: A RAND/UCLA modified Delphi panel study (November 13, 2024)
• A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis by Mayo 2012 Stage in the United States (November 13, 2024)
• United States (US) Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Phase Chronic Myeloid Leukemia (CML) (November 6, 2024)
• Access to Specialty Medicines with Alternative Funding Programs: A Descriptive Survey of Patient Experience (October 17, 2024)
• A Descriptive Survey of Patient Experiences with Alternative Funding Programs Among Patients with Bleeding Disorders and by Income Level (September 14, 2024)
• Modified Delphi panel consensus recommendations for management of severe aplastic anemia (August 13, 2024)
• Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorder (June 23, 2024)
• Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy (June 12, 2024)
• Worse Health Outcomes and Survival of Patients with Severe Hypertriglyceridemia After Acute Pancreatitis (June 2, 2024)
• Development and Validation of Clinical Criteria to Identify Familial Chylomicronemia Syndrome (FCS) in North America (June 2, 2024)
• Increasing Prevalence and Incidence of AL Amyloidosis Among Older Adults in the US (May 28, 2024)
• Understanding the Burden of Illness in People with Nonrelapsing Secondary Progressive Multiple Sclerosis in the United States: A Matched-cohort Study (April 18, 2024)
• Value of next generation sequencing (NGS) testing in advanced cancer patients (April 2, 2024)
• Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria (March 21, 2024)
• Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel (March 17, 2024)
• Clinical and Economic Burden in People with Relapsing-Remitting Multiple Sclerosis in the United States: A Matched-Cohort Study (March 2, 2024)
• Reduced mortality, complications, and economic burden among medicare beneficiaries receiving influenza antivirals (February 13, 2024)
• Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique (January 31, 2024)
• Determinants of Higher Cost and Inpatient Hospitalization Among Patients with AL Amyloidosis (November 15, 2023)
• Real-World Effectiveness of Omalizumab in Patients Treated for Chronic Spontaneous Urticaria (November 13, 2023)
• Efficacy of a Patient-Engagement Platform in Reducing Uncontrolled Hypertension in Community Health Clinics (November 11, 2023)
• Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly (ADP-ribose) polymerase inhibitor (PARPi) + novel hormonal therapy (NHT) combination therapy (November 2, 2023)
• Identifying Adult Patients with Nonrelapsing Secondary Progressive Multiple Sclerosis Using Algorithms in US-based Healthcare Databases (October 16, 2023)
• Clinical and economic burden of patients with and without light chain (AL) amyloidosis: A matched case-control analysis of insurance claims (October 16, 2023)
• A Longitudinal Analysis of Multiple Sclerosis Phenotype Transitions Using Medical Charts in the United States (October 16, 2023)
• Artificial Intelligence in U.S. Health Care Delivery (October 12, 2023)
• Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis (September 11, 2023)
• Efficacy of a Patient-Engagement Platform in Reducing Uncontrolled Hypertension in Community Health Clinics (September 9, 2023)
• The Impact of Disease Severity on the Clinical and Economic Burden of AL Amyloidosis (August 1, 2023)
• Treatment Patterns in Patients With Newly Diagnosed AL Amyloidosis (August 1, 2023)
• Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic (July 1, 2023)
• Implications of the Inflation Reduction Act Price Setting Provisions on Post-approval Indications for Small Molecule Medicines (June 19, 2023)
• Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer (June 7, 2023)
• Healthcare utilization and direct medical costs of Huntington’s disease among Medicaid beneficiaries in the United States (June 5, 2023)
• Implications of the Inflation Reduction Act Price Setting Provisions on Post-approval Indications for Small Molecule Medicines (May 31, 2023)
• RAND/UCLA Modified Delphi Panel on the Severity, Testing, and Medical Management of PIK3CA-Related Spectrum Disorders (PROS) (May 31, 2023)
• Value of Next Generation Sequencing (NGS) Using the OncoExTra™ Test in Advanced Cancer Patients (May 9, 2023)
• Potential Health and Economic Outcomes of a Blood-Based Genomic Test as a Prescreen for Lung Cancer in the US Medicare Population (May 9, 2023)
• Identifying Adult Patients with Nonrelapsing Secondary Progressive Multiple Sclerosis Using Algorithms in US-based Healthcare Databases (May 8, 2023)
• Cost Impact of Next Generation Sequencing Testing in NSCLC With and Without RNA Sequencing (May 8, 2023)
• Beyond Symptoms Alleviation: Population-level Benefits of COVID-19 Oral Direct-acting Antiviral (DAA) Treatment and Resulting Decreases in Infectivity and Transmission (May 8, 2023)
• Healthcare Resource Utilization and Cost Burden of Facial Angiofibroma Associated with Tuberous Sclerosis Complex: A Real-World Claims Database Analysis in the United States (May 8, 2023)
• An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy (April 10, 2023)
• Medicines account for just 1% of the growth in US hospital spending (March 7, 2023)
• Are medicines driving hospital spending increases? (March 7, 2023)
• Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib (March 2, 2023)
• Real-world vs Guideline-Based Treatments for Chronic Spontaneous Urticaria Among Commercially Insured vs Medicaid Patients in the United States (February 24, 2023)
• Expert Consensus on the Use of On-Demand Treatments for OFF Episodes in Parkinson's Disease: A Modified Delphi Panel (February 6, 2023)
• Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide (December 22, 2022)
• Impact of early detection on cancer curability: A modified Delphi panel study (December 21, 2022)
• In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database (December 13, 2022)
• Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis (November 15, 2022)
• Implications of the Inflation Reduction Act on Post-Approval Research & Development of Biopharmaceutical Medicines (November 9, 2022)
• Development and Validation of a Claims-Based Algorithm to Identify Patients With Neuromyelitis Optica Spectrum Disorder (October 26, 2022)
• Diagnostic amyloid light chain amyloidosis hospitalizations associated with high acuity and cost: analysis of the Premier Healthcare Database (October 21, 2022)
• Expert consensus on the management of infusion-related reactions (IRRs) presenting with pain in patients receiving crizanlizumab (October 20, 2022)
• The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis (October 18, 2022)
• Mortality and Economic Burden of Seasonal Influenza Among Elderly Medicare Beneficiaries With and Without Antiviral Treatment (October 11, 2022)
• Real-world Treatment Patterns for Chronic Spontaneous Urticaria: Is Omalizumab Associated With Reduced Corticosteroid Use? (October 11, 2022)
• Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer treated with alpelisib (September 30, 2022)
• Apremilast Adherence in Psoriasis and Psoriatic Arthritis Patients in the Telehealth Setting versus the In-person Setting During the COVID-19 Pandemic (September 7, 2022)
• Diagnostic hospitalization and associated costs in patients with amyloid light-chain amyloidosis (September 4, 2022)
• National burden of achondroplasia: an analysis of the National Inpatient and Nationwide Ambulatory Surgery Samples (August 30, 2022)
• Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis (August 22, 2022)
• Clinical Benefits of Accelerated Approval (July 26, 2022)
• Clinical Benefits of Accelerated Approval (July 26, 2022)
• Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database (June 15, 2022)
• Management, Safety, and Efficacy of Osilodrostat Treatment in US Patients With Non-pituitary Cushing’s Syndrome: Results From the ILLUSTRATE Study (June 13, 2022)
• Dosing and Titration of Osilodrostat in a Real-World Cohort of US Patients With Endogenous Cushing’s Disease: Analysis of the ILLUSTRATE Study (June 13, 2022)
• Use of On-Demand Treatments for OFF Episodes in Parkinson's Disease: Guidance From a RAND/UCLA Modified Delphi Consensus Panel (May 26, 2022)
• An Adaptation of the RAND/UCLA Modified Delphi Panel Method in the Time of COVID-19 (May 20, 2022)
• Clinical, Humanistic, and Economic Outcomes of Next-Generation Sequencing Tests in Cancer Management of Patients with Advanced Cancer in the United States: Systematic Literature Review (May 17, 2022)
• Cost of Neuromyelitis Optica Spectrum Disorder Misdiagnosis (May 17, 2022)
• Pharmacological treatment patterns after initiation of oral carbidopa/levodopa among patients with Parkinson's Disease (May 17, 2022)
• Diagnostic hospitalization and associated costs in patients with amyloid light-chain amyloidosis (May 17, 2022)
• Discrimination in Cost Effectiveness (May 16, 2022)
• Claims-based Algorithms to Identify Persons with Severe Hemophilia A (May 16, 2022)
• An Adaptation of the RAND/UCLA Modified Delphi Panel Method in the Time of COVID-19 (May 16, 2022)
• Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use (May 6, 2022)
• Epidemiology of Huntington’s Disease in the United States Medicare and Medicaid Populations (April 28, 2022)
• Cost of cancer management by stage of diagnosis among Medicare beneficiaries (April 20, 2022)
• Use of On-Demand Treatments for OFF Episodes in Parkinson’s Disease: Guidance From a RAND/UCLA Modified Delphi Consensus Panel (March 29, 2022)
• Testing a Claims-Based Algorithm to Identify Patients with Neuromyelitis Optica Spectrum Disorder (March 29, 2022)
• Testing a Claims-Based Algorithm to Identify Patients With Neuromyelitis Optica Spectrum Disorder (February 24, 2022)
• Real-world impact of disease on functioning and activity: what is missed when using general instruments to estimate quality-adjusted life years (February 1, 2022)
• Effect of Intravesical Chemotherapy on the Survival of Patients with Non-Muscle-Invasive Bladder Cancer Undergoing Transurethral Resection: A Retrospective Cohort Study Among Older Adults (December 23, 2021)
• Dasatinib treatment patterns after pleural effusion among patients with chronic myeloid leukemia (December 14, 2021)
• Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States (December 11, 2021)
• Estimation of Hospital Share of Gross Profits for Physician-Administered Medicines Reimbursed by Commercial Insurers (December 8, 2021)
• Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis (December 1, 2021)
• Healthcare Resource Utilization and Costs of Patients with AL Amyloidosis: An Analysis of Hospitalizations in the Premier Database (November 5, 2021)
• Expert Consensus on the Testing and Medical Management of PIK3CA-Related Overgrowth Spectrum (October 28, 2021)
• Costs for Treating Patients With Ulcerative Colitis With Vedolizumab or Adalimumab Based on Endoscopic Improvement Data From the VARSITY Trial (October 24, 2021)
• Biological Initiation Risk in Psoriatic Arthritis Patients Starting Treatment with Apremilast vs. Methotrexate: 1-Year Retrospective Analysis of a US Claims Database (October 19, 2021)
• Effectiveness of Relapsing Multiple Sclerosis Patients Switching to Teriflunomide Following Disease Progression in a Real-World Setting (October 13, 2021)
• Using cognitive interviews to develop a conceptual claims-based algorithm to identify patients with neuromyelitis optica spectrum disorder (October 13, 2021)
• Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy (September 9, 2021)
• Biologic initiation rates in psoriasis after first-line systemic use of apremilast vs methotrexate (September 1, 2021)
• Developing an emergency department order set to treat acute pain in sickle cell disease (August 9, 2021)
• Reduced access to care among older American adults during CoVID-19 pandemic: Results from a prospective cohort study (July 21, 2021)
• Societal Benefits from Pharmaceutical Innovation Far Surpass Benefits to Manufacturers (July 8, 2021)
• Cardiovascular Disease Burden Before Hereditary Transthyretin Amyloidosis Diagnosis Among Medicare Beneficiaries (June 29, 2021)
• Cardiovascular Disease Burden Before Hereditary Transthyretin Amyloidosis Diagnosis (June 17, 2021)
• Estimates of Stage-Specific Preclinical Sojourn Time Across 21 Cancer Types (June 4, 2021)
• Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors (May 19, 2021)
• National Burden of Achondroplasia in Adults and Children: An Analysis of the National Inpatient Sample (May 18, 2021)
• Use of Commercial Claims Data to Estimate Transthyretin-Amyloid Cardiomyopathy Prevalence and Incidence in the US (May 17, 2021)
• Cardiovascular Symptom Burden Prior to Diagnosis of Transthyretin Amyloidosis Among Medicare Beneficiaries (May 15, 2021)
• Symptom Burden and Healthcare Utilization Before Diagnosis of Transthyretin-Mediated Amyloidosis Among Medicare Beneficiaries (April 17, 2021)
• Use of Commercial Claims Data to Estimate Hereditary Transthyretin-Mediated Amyloidosis Prevalence and Incidence in the US (April 17, 2021)
• Burden of illness among US Medicare beneficiaries with late-onset Huntington’s disease (April 17, 2021)
• Biologic Initiation Risk in Systemic-Naïve Psoriasis Patients With Comorbid Psoriatic Arthritis Starting Treatment With Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database (April 12, 2021)
• Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries (April 12, 2021)
• Burden of illness among US Medicare beneficiaries with late-onset Huntington’s disease (April 12, 2021)
• Healthcare utilization and costs among US Medicaid beneficiaries with Huntington’s disease (April 12, 2021)
• The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis (January 11, 2021)
• Cost-effectiveness of results-based financing of maternal and child health services in Zimbabwe: a controlled pre-post study (December 25, 2020)
• Prevalence of influenza vaccination among adults with high-risk conditions, United States, 2019 (December 22, 2020)
• Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method (December 8, 2020)
• Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method (December 7, 2020)
• Survival prediction for bladder cancer using machine learning: development of BlaCaSurv online survival prediction application (November 16, 2020)
• Epidemiology of Huntington’s disease in the US Medicaid population (October 29, 2020)
• Development of a Severity Classification System for Sickle Cell Disease (October 28, 2020)
• Healthcare resource use and cost in antifibrotic-treated vs untreated patients with idiopathic pulmonary fibrosis (IPF) in the US Medicare population (October 18, 2020)
• Machine Learning to Predict 5-Year Survival among Pediatric Acute Myeloid Leukemia Patients and Development of OSPAM-C Online Survival Prediction Tool (October 1, 2020)
• Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States (October 1, 2020)
• Cardiovascular Burden Prior to Diagnosis of Hereditary Transthyretin Amyloidosis (September 30, 2020)
• Predicting CoVID-19 community mortality risk using machine learning and development of an online prognostic tool (September 28, 2020)
• The Patient Journey Prior to Diagnosis of Hereditary Transthyretin Amyloidosis (September 14, 2020)
• Healthcare utilization and cost burden at the end of life among Medicare beneficiaries with Huntington’s disease (September 12, 2020)
• Epidemiology of Huntington’s disease in the US Medicaid population (September 12, 2020)
• Medicines are not the major driver of hospital spending increases (September 11, 2020)
• Burden of Nasal Polyps in the United States (September 1, 2020)
• Healthcare Use and Costs Among Medicare Enrollees on Pirfenidone Versus Nintedanib for Idiopathic Pulmonary Fibrosis (August 27, 2020)
• Guidelines for Management of Urgent Symptoms in Patients With Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified Rand/UCLA Delphi Process (August 24, 2020)
• Outcomes in Patients With IPF Treated With Antifibrotic Therapies Compared With Untreated Patients in the US Medicare Population (August 5, 2020)
• Epidemiology of COVID-19 and Predictors of Recovery in the Republic of Korea (July 30, 2020)
• Spending on Medicines Accounts for a Small Share of Hospital Spending Increases (July 28, 2020)
• The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey (July 13, 2020)
• Developing an Emergency Department Order Set for Sickle Cell Disease Acute Pain (July 8, 2020)
• Hospital Share of Gross Profits for Physician-Administered Oncology Medicines Reimbursed by Commercial Insurers (July 6, 2020)
• Persistence With Abatacept Versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Positive Anti-Cyclic Citrullinated Peptide/Rheumatoid Factor or Other Poor Prognostic Factors (June 3, 2020)
• Epidemiology of Huntington’s disease (HD) in the US Medicare population (May 28, 2020)
• Healthcare utilization and costs in beneficiaries with Huntington’s disease in the US Medicare population (May 28, 2020)
• The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data (May 25, 2020)
• Cardiovascular Burden Prior to Diagnosis of Hereditary Transthyretin Amyloidosis (May 23, 2020)
• Real-World Impact of Disease on Functioning and Activity: A Cross-Sectional Study of the National Health and Nutrition Examination Survey (May 18, 2020)
• Hospital Share of Profits from Physician-Administered Medicines (May 18, 2020)
• Projected Lifetime Clinical Value of a Multicancer Early Detection Test (May 18, 2020)
• Healthcare utilization and costs by disease stage in beneficiaries with Huntington’s disease in the US Medicare population (May 18, 2020)
• Methods for Analyzing the Type and Timing of Life Science Industry-Funded Publications (May 18, 2020)
• Healthcare Resource Utilization and Costs in Medicare Beneficiaries With Parkinson's Disease (May 1, 2020)
• National Trends in Admission and In-Hospital Mortality of Patients With Lung Cancer in the United States, 2012-2016 (May 1, 2020)
• Despite Increases in Rate of Hospitalization, In-Hospital Mortality and Admission Costs Associated With Melanoma of the Skin Have Remained Stable From 2012-2016 (May 1, 2020)
• National Trends in Admission and In-Hospital Mortality of Patients With Pancreas Cancer in the United States (US), 2012-2016 (May 1, 2020)
• In-Hospital Mortality For Breast Cancer in the United States, 2012-2016 (May 1, 2020)
• Stability of Hospital Cost for US Inpatient Cancer Care From 2012-2016 (May 1, 2020)
• United States Patients’ Perspective of Living With Migraine: Country-Specific Results From the Global “My Migraine Voice” Survey (April 12, 2020)
• The Humanistic and Economic Burden of Pediatric Focal Seizures in the United States (April 6, 2020)
• Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder (February 7, 2020)
• Burden of disease in pediatric narcolepsy: a claims-based analysis of health care utilization, costs, and comorbidities (February 1, 2020)
• The economic burden of caregiving in epilepsy: An estimate based on a survey of US caregivers (January 17, 2020)
• Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy (January 1, 2020)
• Risk of hospitalization among patients with epilepsy using long versus short half-life adjunctive antiepileptic drugs (January 1, 2020)
• Prevalence and Predictors of Routine Prostate-specific Antigen Screening in Medicare Beneficiaries in the USA: Retrospective Cohort Analysis Using Machine Learning (December 31, 2019)
• A Time-and-Motion Study of Chemotherapy Administration in Metastatic Breast Cancer (December 10, 2019)
• Economic Burden of Neurologic Toxicities Associated with Treating Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States (December 7, 2019)
• Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel (December 7, 2019)
• Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder (December 4, 2019)
• Evaluation of Real-World Persistence in Early-Line Abatacept versus Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis Patients with Anti Citrullinated Protein Antibody or Rheumatoid Factor Positivity (November 8, 2019)
• Burden of Illness Among Patients with Hereditary Transthyretin (hATTR) Amyloidosis (November 2, 2019)
• Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data (November 1, 2019)
• Hospital Costs Associated with Neurologic Adverse Events in Patients with Diffuse Large B-Cell Lymphoma: A Study Based on the United States National Inpatient Sample (October 31, 2019)
• Epidemiology of Hereditary Transthyretin (hATTR) Amyloidosis: A Real-World Analysis of a US Commercially Insured Population (October 31, 2019)
• Impact of Omalizumab Treatment on Asthma-Related Health Care Resource Utilization in a Real-world Data Set From a Managed Care Plan (October 29, 2019)
• Real-world Treatment Utilization of Sodium Oxybate in Pediatric Patients With Narcolepsy: An Analysis of Claims Data (October 29, 2019)
• Real-world Treatment Utilization of Sodium Oxybate in Adult Patients With Narcolepsy: An Analysis of Claims Data (October 29, 2019)
• Healthcare Resource Use and Costs in Patients With Idiopathic Pulmonary Fibrosis (IPF) in the US Medicare Population (October 19, 2019)
• Determinants of Generic Drug Use Among Medicare Beneficiaries: Predictive Modelling Analysis Using Artificial Intelligence (October 17, 2019)
• Real-world Treatment Utilisation of Sodium Oxybate in Paediatric Patients With Narcolepsy: An Analysis of Claims Data (September 20, 2019)
• Real-world Treatment Utilisation of Sodium Oxybate in Adult Patients With Narcolepsy: An Analysis of Claims Data (September 20, 2019)
• Impact of second-generation antipsychotic side-effects on functioning from a schizophrenia patient perspective: European perspective of a global patient centered survey (September 7, 2019)
• Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies (September 1, 2019)
• Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States (September 1, 2019)
• Hospitals collect significant revenues from physician-administered drugs (July 31, 2019)
• Cumulative net savings from chronic hepatitis C cures are expected to reach $53 billion by 2028 (July 29, 2019)
• Untangling the Clinical and Economic Burden of Hospitalization for Cardiac Amyloidosis in the United States (July 15, 2019)
• Cost-Effectiveness of Results-Based Financing in Zimbabwe: A Controlled Pre-Post Study (July 15, 2019)
• Burden of Living with Migraine: Results for United States from the “My Migraine Voice” Survey (July 11, 2019)
• Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data (July 1, 2019)
• Epidemiology of Hereditary Transthyretin (hATTR) Amyloidosis: A Real-World Analysis of a US Commercially Insured Population (June 22, 2019)
• Treatment Patterns Among Patients With Relapsed Follicular Lymphoma (June 13, 2019)
• Medical Costs Associated With Relapse Among Patients With Follicular Lymphoma (June 13, 2019)
• Real-World Evaluation of Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors (June 12, 2019)
• Characteristics of Ambulatory Surgical Visits for Chronic Rhinosinusitis with Nasal Polyps (June 6, 2019)
• How does the Cox maze procedure compare? Cost-effectiveness analysis of alternative treatments of atrial fibrillation (June 1, 2019)
• Use of a Modified Delphi Panel to Define Value of Combination Therapy in Oncology (May 26, 2019)
• The Burden of Pediatric Partial Onset Seizures: A Review of the Literature (May 21, 2019)
• The Impact of Second-Generation Antipsychotic Side Effects on Functioning From a Schizophrenia Patient Perspective: A Global Patient Centered Survey (May 18, 2019)
• Hospitalizations in Adult Patients with Schizophrenia Treated with Oral Atypical Antipsychotics: A Real-World Study Using US Claims Data (May 18, 2019)
• Modeling the Mortality Impact of Budget Thresholds (May 18, 2019)
• How Much Do Individuals Value Access to Innovative Lung Cancer Therapies? A Revealed Preference Survey of Healthy Adults in the United States (US) (May 18, 2019)
• Rates of Adherence and Persistence of Antifibrotic Therapies in the US Medicare Population (May 17, 2019)
• Health Care Cost and Utilization Before and After Diagnosis in Pediatric Patients With Newly Diagnosed Narcolepsy: A Claims-based Analysis (May 4, 2019)
• Risk of Hospitalization in Patients with Uncontrolled Epilepsy Treated with a Long Versus Short Half-Life Adjunctive Antiepileptic Medication (May 4, 2019)
• Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder (April 1, 2019)
• Reducing psychiatric care intensity: Choice of antipsychotic matters (March 25, 2019)
• Lower Medical Cost Associated with Aripiprazole Once-Monthly Compared to Oral Atypical Antipsychotics in Patients with Schizophrenia (March 25, 2019)
• Comparison of olaparib versus bevacizumab in the second-line maintenance setting using value frameworks (March 25, 2019)
• Costs associated with unplanned readmissions among patients with heart failure with and without hyponatremia (March 15, 2019)
• Potential Delays in Diagnosis of Idiopathic Pulmonary Fibrosis in Medicare Beneficiaries (March 1, 2019)
• Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment (February 1, 2019)
• Protecting the gains: What changes are needed to prevent a reversal of the downward cardiovascular disease mortality trend? (January 1, 2019)
• Increased Clinical and Economic Burden Associated With Peripheral Intravenous Catheter-Related Complications: Analysis of a US Hospital Discharge Database (January 1, 2019)
• Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers (January 1, 2019)
• Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder (January 1, 2019)
• Secondary prevention of diabetes through workplace health screening (December 26, 2018)
• Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data (December 1, 2018)
• Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USA (December 1, 2018)
• A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States (December 1, 2018)
• Chemotherapy-Induced Nausea and Vomiting (CINV) and Drivers of Antiemetic Prescribing: Results of a Qualitative In-Practice Study of Clinicians From Various Settings (November 10, 2018)
• Understanding Patterns of 30-Day Readmission in Patients with Cardiac Amyloidosis (November 10, 2018)
• Cost–effectiveness of results-based financing, Zambia: a cluster randomized trial (November 1, 2018)
• Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder (November 1, 2018)
• The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States (November 1, 2018)
• Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis (October 25, 2018)
• Better medication adherence to atypical antipsychotics is associated with lower psychiatric hospitalization rates and costs in bipolar I disorder (October 23, 2018)
• Defining Value-Based Pricing of Drugs (October 23, 2018)
• The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions (October 10, 2018)
• Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness (October 2, 2018)
• Health care resource use, costs, and diagnosis patterns in patients with schizophrenia and bipolar disorder: Real-world evidence from US claims databases (October 1, 2018)
• Bending the curve with patient identification and treatment in osteoporosis (September 28, 2018)
• Disparities in First-Line Treatment Initiation Among US Medicare Beneficiaries With Myelodysplastic Syndromes (September 12, 2018)
• Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400mg (AOM 400) Versus Oral Antipsychotics in Patients With Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data (September 11, 2018)
• Differences in treatment outcomes among patients with major depressive disorder and without comorbid substance abuse (September 8, 2018)
• Impact of comorbid substance abuse on healthcare utilization and costs in patients with bipolar I disorder treated with atypical antipsychotics (September 8, 2018)
• Reducing Healthcare Costs in Antidepressant Non-Responders: Does Timing of Antipsychotic Augmentation Matter? (September 8, 2018)
• Adjunctive Atypical Antipsychotic Choice Affects Healthcare Utilization in Major Depressive Disorder (MDD) (September 8, 2018)
• Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder (September 1, 2018)
• Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis (August 30, 2018)
• Economic and Clinical Outcomes of Hospital Care in Patients with Cardiac Amyloidosis (August 25, 2018)
• Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database (August 13, 2018)
• First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA (August 1, 2018)
• A Conversational War of Attrition (July 1, 2018)
• Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA (July 1, 2018)
• Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA (July 1, 2018)
• Untangling Hospitalizations in Systemic Amyloidosis: Patient Characteristics, Economic Cost, and Clinical Outcomes (June 14, 2018)
• Treatment Patterns of Anti-Tumor Necrosis Factor and Anti-Integrin Therapies in Inflammatory Bowel Disease (IBD): Analysis of U.S. Insurance Claims (June 2, 2018)
• Disease Burden in Pediatric Narcolepsy: A Claims-based Analysis of Health Care Utilization and Costs and Medical Comorbidity (June 2, 2018)
• Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data (June 1, 2018)
• Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA (June 1, 2018)
• Epidemiology of AL Amyloidosis: A Real-World Study Using US Claims Data (May 22, 2018)
• Healthcare Utilization and Cost Among Patients with Hereditary Transthyretin Amyloidosis (hATTR) (May 19, 2018)
• Reduction in Hospitalizations and Medical Cost Savings Associated With Early Use of Adjunctive Atypical Antipsychotics in Major Depressive Disorder (May 19, 2018)
• Changes in Healthcare Resource Use and Costs Associated With the Use of Adjunctive Atypical Antipsychotics in Major Depressive Disorder (May 19, 2018)
• Impact of Initiating Long-Acting Injectables (LAI) on All-Cause and Psychiatric-Specific Hospitalization in Patients with Bipolar I Disorder (May 19, 2018)
• Reduced Risk of Hyperprolactinemia Among Patients Treated With Atypical Antipsychotics That Are Associated With Low or No Prolactin Elevation (May 19, 2018)
• Healthcare Costs Associated with Hyperprolactinemia in the United States (May 19, 2018)
• Healthcare Utilization and Costs in Commercially Insured Patients with AL Amyloidosis (May 10, 2018)
• Identification of Undiagnosed Hyperlipidemia: Do Work Site Screening Programs Work? (May 1, 2018)
• Systematic bias in predictions of new drugs’ budget impact: analysis of a sample of recent US drug launches (May 1, 2018)
• Disease Burden of Hereditary Transthyretin Amyloidosis (hATTR): Analysis of Real-World Data (April 23, 2018)
• The Impact of Delaying Adjunctive Treatment with Atypical Antipsychotic Medication for Major Depressive Disorder on Changes in Healthcare Resource Use and Medical Costs (April 23, 2018)
• Real-World Health Care Utilization and Costs in Patients with Newly Diagnosed AL Amyloidosis (April 23, 2018)
• Atypical Anti-Psychotics Predicts Inpatient Hospitalization and Costs in Bipolar Disorder I (April 23, 2018)
• Estimated prevalence of undiagnosed atrial fibrillation in the United States (April 12, 2018)
• Impact of Side Effects Due to Second-Generation Antipsychotics on the Functioning of Patients With Schizophrenia: An Observational, Patient Centered, Web Survey (April 4, 2018)
• Healthcare Utilization and Cost in Schizophrenia and Bipolar Disorder: Real-world Evidence from US Claims Databases (April 4, 2018)
• Medication Adherence and Discontinuation in Patients with Schizophrenia Treated with Aripiprazole Once-monthly Long-acting Injectable Versus Those Treated with Oral Antipsychotics (April 4, 2018)
• Schizophrenia and Bipolar Disorder Diagnosis Patterns: Real-World Evidence From US Claims Databases (April 4, 2018)
• Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis (March 6, 2018)
• Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia (January 22, 2018)
• Treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) (January 18, 2018)
• The economic burden of bipolar I disorder in the United States in 2015 (January 15, 2018)
• Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review (January 4, 2018)
• Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review (January 1, 2018)
• Healthcare Utilization and Costs in Commercially Insured Patients With AL Amyloidosis (December 9, 2017)
• Epidemiology of AL Amyloidosis in a US Commercially Insured Population (December 7, 2017)
• Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity (December 1, 2017)
• All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics (November 3, 2017)
• Patient Outcomes, Health Care Resource Use, and Costs Associated with High versus Low HEDIS Asthma Medication Ratio (November 1, 2017)
• Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes Care (November 1, 2017)
• Specialty Visits and Testing Patterns Prior to IPF Diagnosis in Medicare Patients (October 28, 2017)
• Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors (October 28, 2017)
• Predictive Factors of Carcinoid Syndrome (CS) among Patients with Gastrointestinal Neuroendocrine Tumors (GI NETs) (October 19, 2017)
• Healthcare Resource Use and Cost With Brexpiprazole Use in Patients With Major Depressive Disorder (October 16, 2017)
• Incremental Cost of Diffuse Large B Cell Lymphoma Beyond First-Line Therapy: A Retrospective Cohort Analysis (October 16, 2017)
• Cost-Effectiveness Analysis of Long-Acting Injectable Aripiprazole Once-Monthly 400 mg in Bipolar I Disorder (October 16, 2017)
• Budget Impact Analysis of Long-Acting Injectable Aripiprazole Once-Monthly 400 mg in Bipolar I Disorder (October 16, 2017)
• Epidemiology of Gastrointestinal Neuroendocrine Tumors in a US Commercially Insured Population (October 1, 2017)
• The Cost of Hematopoietic Stem-Cell Transplantation in the United States (October 1, 2017)
• Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder (September 29, 2017)
• Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis (September 7, 2017)
• Value-Based Payments and Incentives to Improve Care: A Case Study of Patients with Type 2 Diabetes in Medicare Advantage (September 1, 2017)
• Regional disparities in the quality of stroke care (September 1, 2017)
• Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis (September 1, 2017)
• Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals (August 16, 2017)
• Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center (August 4, 2017)
• Cumulative oral corticosteroid use increases risk of glucocorticoid-related adverse events in patients with newly diagnosed pemphigus (August 1, 2017)
• Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors (August 1, 2017)
• Lanreotide reduces hospital costs for metastatic GEP-NETs (August 1, 2017)
• Care transitions among Latino diabetics: barriers to study enrollment and transition care (August 1, 2017)
• Biochemical Control During Long-term Follow-up of 230 Adult Patients with Cushing Disease: A Multicenter Retrospective Study (August 1, 2017)
• Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data (August 1, 2017)
• Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence (August 1, 2017)
• A systematic literature review of methods of incorporating mortality in cost effectiveness analyses of lipid-lowering therapies (July 1, 2017)
• Hospitalization Costs in Schizophrenia: Long-acting Injectable (LAI) versus Oral Antipsychotic Use (June 17, 2017)
• Inpatient Hospitalizations and Costs in Patients with Schizophrenia Initiating LAIs (June 17, 2017)
• Hospitalization and Costs in Patients with Bipolar Disorder Initiating LAIs (June 17, 2017)
• Treatments and Outcomes of Idiopathic Pulmonary Fibrosis in a Medicare Population Prior to Approval of Anti-fibrotic Therapies (June 7, 2017)
• Testing Leading to the Diagnosis of Idiopathic Pulmonary Fibrosis in Medicare Patients (June 7, 2017)
• Testing Leading to the Diagnosis of Idiopathic Pulmonary Fibrosis in Medicare Patients (June 7, 2017)
• Real-world evidence on the use of three recently approved long acting injectable antipsychotics in the United States: statistical and cost analysis in patients with schizophrenia (June 3, 2017)
• Total and excess costs associated with bipolar I disorder in the United States in 2015 (June 3, 2017)
• Validity and Reliability of Four Value Frameworks for Cancer Drugs (June 2, 2017)
• Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting (June 1, 2017)
• Economic Burden of Bipolar Disorder in the United States: A Systematic Review of the Literature (May 24, 2017)
• Mechanical ventilation in idiopathic pulmonary fibrosis: a nationwide analysis of ventilator use, outcomes, and resource burden (May 22, 2017)
• Measuring the Validity and Reliability of Value Assessment Frameworks for Cancer Drugs: An Evaluation Method (May 20, 2017)
• Medication Adherence and Discontinuation in Medicaid Patients with Schizophrenia Who Initiated a Long-Acting Injectable Antipsychotic Versus Those Who Changed to a Different Oral Antipsychotic Monotherapy (May 20, 2017)
• The Epidemiology of Postpartum Depression (PPD) in a Commercially Insured Population (May 20, 2017)
• Treatment Patterns, Adherence and Clinical Outcomes in Bipolar Disorder Type I: A Systematic Review of Observational Studies (May 20, 2017)
• Budget Impact of Increased Utilization of Palonosetron for the Control of Chemotherapy Induced Nausea and Vomiting in Managed Care (May 20, 2017)
• Estimates of Postpartum Depression Prevalence in a Commercially Insured Population – A Retrospective Study (May 20, 2017)
• Epidemiology of Postpartum Depression in a Medicaid Population – A Retrospective Study (May 20, 2017)
• Impact of Time of Diagnosis on Prevalence of Postpartum Depression in Women with Commercial and Medicaid Health Insurance – A Retrospective Study (May 20, 2017)
• A Systematic Literature Review of Clinical Practice Guidelines for the Treatment of Bipolar Disorder Type I (BD-I) (May 20, 2017)
• Brexpiprazole Use in Long-Term Care Patients With Major Depressive Disorder: Results From a Retrospective Analysis of Long-Term Data (May 20, 2017)
• Adherence and Treatment Patterns in Brexpiprazole Therapy in Long Term Care Patients With Schizophrenia: Results From a Retrospective Analysis of Long-Term Data (May 20, 2017)
• Brexpiprazole Use in Patients With Major Depressive Disorder: Results From a Retrospective Analysis of Longitudinal Prescription Data (May 20, 2017)
• Adherence and Treatment Patterns of Early Adopters of Brexpiprazole Therapy With Schizophrenia – Results From a Retrospective Analysis of Longitudinal Prescription Data (May 20, 2017)
• A Systematic Review of Health Economic Studies on Bipolar Disorder Type I in the United States (May 20, 2017)
• Epidemiology of Bipolar Disorder Type I (BD-I) in the United States: A Systematic Review of the Literature (May 20, 2017)
• A Method for Identifying Peripheral Intravenous (PIV) Catheter-related Complications in a U.S. Hospital Discharge Database (May 20, 2017)
• Medication Adherence and Discontinuation in Medicaid Patients with Dual Diagnoses of Schizophrenia and Bipolar Who Initiated a Long-Acting Injectable Antipsychotic Versus Those Who Changed to a Different Oral Antipsychotic Monotherapy (May 20, 2017)
• Protecting the gains: what changes are needed to prevent a reversal of the downward CVD mortality trend? (May 20, 2017)
• Comparisons of Hospital Readmission Rates in Patients with Bipolar Disorder Receiving Long-acting Injectable Antipsychotics during Hospitalization (May 20, 2017)
• Medication Adherence and Discontinuation in Patients with Bipolar Disorder Who Initiated a Long-Acting Injectable Antipsychotic Versus Those Who Changed to a Different Oral Antipsychotic Monotherapy (May 20, 2017)
• All-cause Inpatient Hospitalizations in Medicaid Patients with Dual Diagnoses of Schizophrenia and Bipolar Disorder who Initiated Long-Acting Injectable Antipsychotics (May 20, 2017)
• Retrospective Analysis of Patients with Ovarian Cancer Receiving Treatment at a Tertiary Care Hospital in India (May 20, 2017)
• The Impact of Different Types of Payer on Healthcare Resource Utilization and Costs Among Cancer Patients in India (May 20, 2017)
• Retrospective Review of Oral Cancer Patients in India: Analysis of Patient Characteristics and Treatment Methods (May 20, 2017)
• Impact of Payer on Healthcare Resource Utilization and Costs Among Ovarian Cancer Patients in India (May 20, 2017)
• Impact of Payer on Healthcare Resource Utilization and Costs Among Breast Cancer Patients in India (May 20, 2017)
• A Retrospective Review of Patient Characteristics and Treatment Methods of Breast Cancer Patients in India (May 20, 2017)
• Impact of Payer on Healthcare Resource Utilization and Costs Among Oral Cancer Patients in India (May 20, 2017)
• Retrospective Review of Cancer Patients in India: Analysis of Patient Characteristics and Treatment Methods (May 20, 2017)
• Comparisons of 30-day Readmission Rates in Patients with Schizophrenia Receiving Long-acting Injectable Antipsychotics during Hospitalization (May 20, 2017)
• Medical Costs Associated with 30-Day Readmissions among Patients with Heart Failure and Persistent Hyponatremia (May 20, 2017)
• End Of Life Costs For Medicare Patients with Idiopathic Pulmonary Fibrosis (May 19, 2017)
• Protecting the gains: what changes are needed to prevent a reversal of the downward CVD mortality trend? (May 18, 2017)
• Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis (May 15, 2017)
• Cost and health care utilization in patients with asthma and high oral corticosteroid use (May 1, 2017)
• The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail (April 1, 2017)
• An approach to using data mining to support early identification of acromegaly (April 1, 2017)
• Expert Panel Recommendations for the Management of Patients with Persistent and Recurrent Cushing’s Disease (April 1, 2017)
• Follow-Up Intervals in Cushing’s Disease: A Multi-Center Study in 230 Patients (April 1, 2017)
• Budget Impact Analysis Comparing Aripiprazole and Aripiprazole Lauroxil Based on Real-World Dosing Patterns (March 27, 2017)
• Treatment Patterns of Lung Neuroendocrine Tumors (NETs) (March 16, 2017)
• Follow-up intervals in patients with Cushing’s disease: recommendations from a panel of experienced pituitary clinicians (March 9, 2017)
• The association between biochemical control and cardiovascular risk factors in acromegaly (March 9, 2017)
• The Use of Real-World Data to Examine Comparative Effectiveness Research and Treatment Patterns in HER2-Negative and Triple-Negative Metastatic Breast Cancer: A Systematic Literature Review (March 3, 2017)
• Hospital cost and length of stay in idiopathic pulmonary fibrosis (February 3, 2017)
• Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs (February 1, 2017)
• Comparative efficacy and safety of nivolumab (nivo) vs relevant treatments (txs) in pretreated non-squamous (NSQ) advanced non-small cell lung cancer (aNSCLC): Results from a systematic literature review (SLR) and indirect treatment comparisons (ITCs) of randomized controlled trials (RCTs) (January 27, 2017)
• Comparative efficacy and safety of nivolumab (nivo) vs relevant treatments (txs) in pretreated squamous (SQ) advanced non-small cell lung cancer (aNSCLC): Results from a systematic literature review (SLR) and indirect treatment comparisons (ITCs) of randomized controlled trials (RCTs) (January 27, 2017)
• Treatment Patterns of Gastrointestinal (GI) Neuroendocrine Tumors (NETs) (January 19, 2017)
• Consensus Treatment Guidelines for Urgent Symptoms in Cholangiocarcinoma Patients with Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process (January 19, 2017)
• The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions (January 1, 2017)
• Cost Effectiveness of Metal Stents in Relieving Obstructive Jaundice in Patients with Pancreatic Cancer (December 27, 2016)
• Early Treatment Initiation in Myelodysplastic Syndromes (MDS) Produces Higher Rate of and Earlier Transfusion Independence (December 3, 2016)
• Estimating the Economic Burden of Caregiving in Epilepsy (December 2, 2016)
• The Caregiver’s Direct Medical Costs in Epilepsy (December 2, 2016)
• Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis (November 11, 2016)
• Incidence of Peripheral Intravenous Catheter-Related Complications in a U.S. Hospital Discharge Database (November 6, 2016)
• Corticosteroid-related toxicity in patients with chronic idiopathic urticaria–chronic spontaneous urticaria (November 1, 2016)
• Incidence and Prevalence of Acromegaly in the United States: A Claims-Based Analysis (November 1, 2016)
• A Novel Method for Evaluating Value Assessment Frameworks (October 29, 2016)
• Characteristics of Patients with Cystic Fibrosis Using Twice vs Once Daily Dornase Alfa Regimens (October 27, 2016)
• Validity and Reliability of Three Value Frameworks for Oncology Therapeutics: A Pilot Study (October 26, 2016)
• Longitudinal Changes in Comorbidity Rates in Patients With Idiopathic Pulmonary Fibrosis: Analysis of Medicare Data (October 22, 2016)
• Mortality Risk of Patients with Idiopathic Pulmonary Fibrosis (October 22, 2016)
• Cardiovascular Burden and Medication Use Among Patients with Idiopathic Pulmonary Fibrosis (October 22, 2016)
• How Accurate are Budget Impact Predictions for New Drugs? An Empirical Analysis (October 3, 2016)
• Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis (October 1, 2016)
• Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis (October 1, 2016)
• Epidemiology of Neuroendocrine Tumors (NET) of the Lung in the US: Analysis of 2 Large Insurance Claims Databases (September 30, 2016)
• Economic Burden of Illness of Malignant Lung Neuroendocrine Tumors (NET) (September 30, 2016)
• Epidemiology of Gastrointestinal Neuroendocrine Tumors (GI NET) in the US: Analysis of 2 Large Insurance Claims Databases (September 30, 2016)
• Economic Burden of Illness of Malignant Gastrointestinal Neuroendocrine Tumors (NET) (September 30, 2016)
• Economic Burden of Illness of Malignant Lung Neuroendocrine Tumors (NET) (September 27, 2016)
• Economic Burden of Illness of Malignant Gastrointestinal Neuroendocrine Tumors (NET) (September 27, 2016)
• Epidemiology of Neuroendocrine Tumors (NET) of the Lung in the US: Analysis of 2 Large Insurance Claims Databases (September 22, 2016)
• Risk of Cardiovascular Comorbidities in Patients with Idiopathic Pulmonary Fibrosis: Analysis of Medicare Data (September 3, 2016)
• Defining High-Quality Palliative Care in Oncology Practice: An American Society of Clinical Oncology/American Academy of Hospice and Palliative Medicine Guidance Statement (September 1, 2016)
• Healthcare Burden of Allergic Status in Patients with Severe Asthma: A Matched-Cohort Real-World Evidence Study (July 29, 2016)
• Can Patient and Provider Education Increase Insulin Initiation? (June 10, 2016)
• Reliability and Consistency of Three Value Frameworks for Oncology Therapeutics (May 23, 2016)
• Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in United States Hospitals (May 21, 2016)
• Orals Versus Subcutaneous Administration of Disease Modifying Therapies: A Comparison of Characteristics of Patients Diagnosed With Relapsing Remitting Multiple Sclerosis (May 21, 2016)
• Fingolimod Versus Teiflunomide: Characteristics of Patients Diagnosed With Relapsing Remitting Multiple Sclerosis and Taking Oral Disease Modifying Therapies (May 21, 2016)
• Health Economic Evaluation of Interferon Beta 1b Versus 1a for Patients Diagnosed With Relapsing Remitting Multiple Sclerosis (May 21, 2016)
• Fingolimod Versus Teiflunomide: Health Care Costs Associated With Patients Diagnosed With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Therapies in the United States (May 21, 2016)
• Health Economic Evaluation of Orally Versus Subcutaneously Administered Disease Modifying Therapies for Patients Diagnosed With Relapsing Remitting Multiple Sclerosis (May 21, 2016)
• Comparison of Characteristics of Patients Diagnosed With Relapsing Remitting Multiple Sclerosis and Taking Subcutaneously Administered Disease Modifying Therapies: Interferon Beta 1b Versus 1a (May 21, 2016)
• Graphical Analysis of Treatment Patterns among Patients with Pancreatic Neuroendocrine Tumors Newly Treated with Cytotoxic Chemotherapy or Targeted Therapy (May 21, 2016)
• Are Financial Incentives in Pay-For-Performance Programs Sufficient? A Case Study of Diabetes Care in Medicare Advantage Plans (May 21, 2016)
• Mortality, Costs, and Length of Stay in Patients with Idiopathic Pulmonary Fibrosis (May 13, 2016)
• Association between Clinical Characteristics and In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis (May 13, 2016)
• Invasive Mechanical Ventilation in Idiopathic Pulmonary Fibrosis: Predictors of Use and Impact on Resource Utilization and Mortality (May 13, 2016)
• Allergic Status is Associated with Increased Number of Asthma Exacerbations (May 13, 2016)
• Cumulative Oral Corticosteroid Use Increases Risk of Glucocorticoid-related Adverse Events in Patients with Pemphigus (May 11, 2016)
• Identification of Potential Markers for Cushing's Disease (May 1, 2016)
• Economic Implications of Instituting Clinical Care Pathways in Metastatic Colorectal Cancer (April 19, 2016)
• Cost Effectiveness of Treatments for Peripheral T-Cell Lymphoma (April 19, 2016)
• The Cost Impact of Non-Infectious Diarrhea in Patients with Carcinoid Syndrome (April 19, 2016)
• Costs and Length of Stay in Hospitalized Patients with Idiopathic Pulmonary Fibrosis: Analysis of the National Inpatient Sample (April 19, 2016)
• Treatment Patterns Among Patients With Cystic Fibrosis Using Twice Daily Dornase Alfa Regimen (April 19, 2016)
• An Economic Evaluation of Brexpiprazole Treatment in Adult Patients with Schizophrenia in the United States (April 17, 2016)
• Expert Consensus Recommendations for Follow-up Intervals in Patients with Cushing's Disease (April 1, 2016)
• Biochemical Control during Long Term Follow up of 230 Patients with Cushing's Disease: A Multi-Center Retrospective Study (April 1, 2016)
• Prevalence of Acromegaly in the United States: A Claims-Based Analysis (April 1, 2016)
• Incidence of Acromegaly in the United States: A Claims-Based Analysis (April 1, 2016)
• Identification of Potential Markers for Acromegaly as an Aid to Diagnosis (April 1, 2016)
• Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals (March 9, 2016)
• Cost and Healthcare Utilization in Asthma Patients with High Oral Corticosteroid-Use (March 4, 2016)
• Elevated immunoglobulin E (IgE) levels are associated with emergency care and other healthcare utilization among asthma patients in a real-world data setting (March 4, 2016)
• Costs of Hematopoietic Stem Cell Transplantation and Associated Conditioning Regimens (February 18, 2016)
• Healthcare and economic impact of diarrhea in patients with carcinoid syndrome (February 14, 2016)
• Novel screening metric for the identification of at-risk peripheral artery disease patients using administrative claims data (February 1, 2016)
• Neighborhood Characteristics Are Associated with Racial and Gender Variation in Walking among Older Adults: the Cardiovascular Health Study (January 21, 2016)
• Carcinoid Syndrome Symptoms in Pancreatic Neuroendocrine Tumors (PNET) and Impact on Healthcare Utilization (January 21, 2016)
• Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study (January 5, 2016)
• Patterns of Pharmacologic Treatment in US Patients with Acromegaly (January 4, 2016)
• The Cost of Hematopoietic Stem Cell Transplantation and Associated Conditioning Regimens (December 5, 2015)
• Incremental healthcare resource utilization and costs in US patients with Cushing’s disease compared with diabetes mellitus and population controls (December 1, 2015)
• Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy (November 20, 2015)
• Patterns of Pharmacotherapy Changes and Switches Suggest Unmet Need in US Patients with Acromegaly (November 19, 2015)
• Health care costs associated with geriatric patients diagnosed with multiple sclerosis taking disease modifying agents in the United States (November 7, 2015)
• Characteristics of Patients With Relapsing Remitting Multiple Sclerosis Taking Once Daily Fingolimod Capsules in the United States (November 7, 2015)
• Characteristics of Patients With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Agents (November 7, 2015)
• Costs Associated with Patients Diagnosed with Relapsing Remitting Multiple Sclerosis Taking Once Daily Fingolimod Capsules in the United States (November 7, 2015)
• Health care resource utilization associated with pediatric patients diagnosed with relapsing remitting multiple sclerosis (November 7, 2015)
• Health care costs associated with patients diagnosed with relapsing remitting multiple sclerosis taking once daily Teriflunomide tablets in the United States (November 7, 2015)
• Healthcare costs associated with patients diagnosed with relapsing remitting multiple sclerosis (November 7, 2015)
• Descriptive Evaluation of Characteristics of Patients Diagnosed With Relapsing Remitting Multiple Sclerosis and Taking Disease Modifying Agents (November 7, 2015)
• Characteristics of Patients With Relapsing Remitting Multiple Sclerosis Taking Once Daily Teriflunomide Tablets in the United States (November 7, 2015)
• Characteristics of geriatric patients diagnosed with multiple sclerosis taking disease modifying agents in the United States (November 7, 2015)
• Characteristics of Pediatric Patients With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Agents (November 7, 2015)
• Descriptive Evaluation of Patient Characteristics and Health Care Resource Utilization of Patients Diagnosed with Malignant Neoplasm of Rectum (November 7, 2015)
• Patient Characteristics and Health Care Resource Utilization of Patients Diagnosed with Prostate Cancer (November 7, 2015)
• Descriptive Evaluation of Patient Characteristics and Health Care Resource Utilization of Patients Diagnosed with Ovarian Cancer (November 7, 2015)
• Descriptive Evaluation of Patient Characteristics and Health Care Resource Utilization of Patients Diagonsed With Malignant Neoplasm of Anus (November 7, 2015)
• Patient Characteristics and Health Care Resource Utilization of Patients Diagnosed with Neoplasm of Colon (November 7, 2015)
• Descriptive Evaluation of Patient Characteristics and Health Care Resource Utilization of Patients Diagnosed with Breast Cancer (November 7, 2015)
• Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage (November 5, 2015)
• Network Meta-Analysis of Treatments for Patients With Type 2 Diabetes Mellitus and Obesity (November 2, 2015)
• Stage 2 hypertension: predictors of failure to achieve blood pressure (November 1, 2015)
• Health Care Resource Use and Costs Associated With Side Effects of High Oral Corticosteroid Use in Asthma: A Claims-Based Analysis (October 26, 2015)
• In-Hospital Length of Stay and Mortality for Patients With Idiopathic Pulmonary Fibrosis (IPF) in the US (October 25, 2015)
• Pharmacoeconomic Modeling of Biosimilars in the US: A Conceptual Framework (October 20, 2015)
• The Cost Impact of Non-Infectious Diarrhea in Patients with Carcinoid Syndrome (October 15, 2015)
• Defining high-quality palliative care in oncology practice: An ASCO/AAHPM Guidance Statement (October 9, 2015)
• Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data (October 7, 2015)
• Financial implications of a hospital early mobility program (October 3, 2015)
• Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States (September 1, 2015)
• An optimal voting procedure when voting is costly (September 1, 2015)
• Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database (July 22, 2015)
• Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use (July 1, 2015)
• Chronic urticaria carries substantial cost burden (July 1, 2015)
• Resource Use and Costs in an Insured Population of Patients with Chronic Idiopathic/Spontaneous Urticaria (June 9, 2015)
• Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients <65 years old in the United States (June 1, 2015)
• The Impact of Genomic Testing on the Recommendation for Radiation Therapy in Patients With Ductal Carcinoma In Situ: A Prospective Clinical Utility Assessment of the 12-Gene DCIS Score™ Result (June 1, 2015)
• Prevalence and Clinical Characteristics of Idiopathic Pulmonary Fibrosis (May 15, 2015)
• Clinical and Economic Burden of Idiopathic Pulmonary Fibrosis (May 15, 2015)
• Validation of an ICD-9 based claims algorithm for identifying patients with chronic idiopathic/spontaneous urticaria (May 1, 2015)
• MDS patient characteristics associated with use of disease-modifying therapy: results of a patient survey (April 29, 2015)
• MDS Conceptual Framework Identifies Unmet Need for HMA-Unresponsive and Transplant-Ineligible Patients (April 29, 2015)
• Population Incidence of MDS Following Hypomethylating Agent (HMA) Treatment Failure: Analysis of US Commercial Claims Data (April 29, 2015)
• Health Care Resource Use and Costs Associated With Side Effects of Oral Corticosteroid Use in Chronic Idiopathic Urticaria (CIU): A Claims-Based Analysis (April 7, 2015)
• Health Care Use and Costs Associated With High vs Low HEDIS Asthma Medication Ratio (April 7, 2015)
• Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma (April 1, 2015)
• A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer (March 17, 2015)
• Biochemical Control and Comorbidities in a US Acromegaly Registry (March 6, 2015)
• A Multi-Center Study of Follow-Up Intervals in Patients with Cushing’s Disease (March 2, 2015)
• Disease Characteristics Associated with Cushing’s Disease: A Multi-Center US Study (March 2, 2015)
• Potential Factors Related to Treatment Changes in Acromegaly Patients: Analysis of a US Prospective Registry (March 2, 2015)
• Treatment Patterns Among US Acromegaly Patients in a Prospective Registry (March 2, 2015)
• Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors (February 28, 2015)
• Inflammation in Patients Receiving Aflibercept, Bevacizumab, or Ranibizumab: Analysis of 936,926 Intravitreal Injections (February 25, 2015)
• Cost-Effectiveness of Bronchial Thermoplasty in Patients with Poorly Controlled, Severe, Persistent Asthma (February 20, 2015)
• Corticosteroid-Related Adverse Events in Chronic Idiopathic Urticaria (February 20, 2015)
• Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review (February 14, 2015)
• Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use (January 27, 2015)
• Congestive Heart Failure: Attributable Costs Within the Managed Care Setting (January 1, 2015)
• Burden of Illness, Annual Healthcare Utilization and Costs Associated with Commercially Insured Patients with Cushing Disease in the United States (January 1, 2015)
• Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States (January 1, 2015)
• Quality of Life Burden Among Patients with Myelodysplastic Syndrome: Analysis of Survey Data (December 6, 2014)
• Incidence of First-Line and Second-Line Myelodysplastic Syndrome in a US Commercial Claims Database (December 6, 2014)
• Healthcare Resource Utilization and Costs among Patients with Myelodysplastic Syndrome Who Failed 1st-Line Therapy (December 6, 2014)
• Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies (December 6, 2014)
• Cost Effectiveness of Treatments After Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS) (December 6, 2014)
• Corticosteroid-Related Adverse Events in Patients with Giant Cell Arteritis: A Claims-Based Analysis (November 14, 2014)
• Lapses in Asthma Control in Patients Who Continued vs. Discontinued Omalizumab (November 6, 2014)
• Real-World First-Line Treatment Patterns among US Carcinoid Syndrome Patients (October 10, 2014)
• The Healthcare and Economic Impact of Diarrhea in US Patients with Carcinoid Syndrome (October 10, 2014)
• Incremental Healthcare Resource Utilization and Costs in U.S. Patients with Cushing’s Disease Compared with Diabetes and Population Controls (October 7, 2014)
• Burden of skeletal-related events in prostate cancer: unmet need in pain improvement (October 2, 2014)
• Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study (September 24, 2014)
• Treatment patterns in Cushing's disease patients in two large United States nationwide databases: application of a novel, graphical methodology (September 23, 2014)
• Clinical Utility of the 12-gene Ductal Carcinoma in situ (DCIS) Score: Impact on Treatment Recommendations (September 14, 2014)
• Health and Economic Consequences of Controlled versus Uncontrolled Surgical Bleeding in Patients Treated with Hemostatic Agents: A Retrospective Analysis of the Premier Perspective Database (September 11, 2014)
• Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases (August 1, 2014)
• Identification of Potential Markers for Cushing's Disease as an Aid to Diagnosis (June 21, 2014)
• Patterns of Pharmacologic Treatment in US Patients with Acromegaly (June 21, 2014)
• Prevalence and Incidence of Chronic Kidney Disease in US Adults with Type 2 Diabetes Mellitus (June 15, 2014)
• U.S. Surgical Specialist Practice Patterns in the Management of Gastroesophageal Reflux Disease (June 8, 2014)
• The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer (June 6, 2014)
• Cost-effectiveness of Cetuximab as first-line treatment for metastatic colorectal cancer in the US (June 2, 2014)
• Myelodysplastic Syndromes Management and Treatment: A Conceptual Framework (June 2, 2014)
• Validation of an ICD-9–Based Claims Algorithm for Identifying Patients With Chronic Idiopathic/Spontaneous Urticaria (May 31, 2014)
• Clinical Utility of the 12-gene DCIS Score™ Result: Impact on Treatment Recommendations (May 30, 2014)
• Defining High Oral Corticosteroid Use in Asthma Patients (May 18, 2014)
• Risk of Corticosteroid-Related Adverse Events in Patients With Asthma With 30 Days or More of Annual Oral Corticosteroid Exposure (May 16, 2014)
• Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer (May 14, 2014)
• Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States (May 12, 2014)
• The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy- Induced Nausea and Vomiting: Systematic Review of the Literature (May 1, 2014)
• Systematic Review and Meta-analysis of Robotic vs Conventional Thyroidectomy Approaches for Thyroid Disease (April 1, 2014)
• Relationship Between HEDIS Measurements and Asthma-Related Outcomes (April 1, 2014)
• Identifying Patients at Risk for High Medical Costs and Good Candidates for Obesity Intervention (March 1, 2014)
• Evaluation of the Prevalence of Chronic Kidney Disease and Rates of Oral Antidiabetic Prescribing in Accordance with Guidelines and Manufacturer Recommendations in Type 2 Diabetic Patients within a Long-Term Care Setting (February 25, 2014)
• Healthcare utilization and costs in children with stable and uncontrolled epilepsy (February 19, 2014)
• At‐Risk Drinking and Outpatient Healthcare Expenditures in Older Adults (February 1, 2014)
• Healthcare utilization and costs in adults with stable and uncontrolled epilepsy (February 1, 2014)
• Effect of the 12-Gene Colon Cancer Assay Results on Adjuvant Treatment Recommendations in Patients with Stage II Colon Cancer (February 1, 2014)
• Cost Effectiveness of Metal Stents in Pancreatic Cancer (January 17, 2014)
• Association Between Hospital Case Volume and the Use of Bronchoscopy and Esophagoscopy During Head and Neck Cancer Diagnostic Evaluation (January 1, 2014)
• A Systematic Literature Review of the Impact of 5-HT3RA Use on Healthcare Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting in the United States (November 2, 2013)
• Consensus development: Within general oncology practice, what constitutes high quality palliative care delivery? (November 1, 2013)
• Assessing the care of geriatric trauma patients: use of quality indicators (October 6, 2013)
• A Systematic Literature Review of the Efficacy and Safety of Octreotide Long-Acting Repeatable (LAR) at Higher than FDA-Approved Doses and/or Frequencies for Treatment of Neuroendocrine Tumors (October 4, 2013)
• Epidemiology and Economic Studies on Patients Diagnosed With Insomnia: A Review of the Literature (September 12, 2013)
• Evaluation of Treatment Patterns and Clinical Trials Published on Patients Diagnosed With Insomnia: A Literature Update (September 12, 2013)
• Evaluation of Associations Among Biomarkers, Correlates and Treatment Efficacy in Clinical Studies in Patients Diagnosed With Non-Psychotic Major Depressive Disorder: A Literature Review (September 12, 2013)
• A Comprehensive Review of Epidemiology and Economic Studies for Patients Diagnosed With Non-Psychotic Major Depressive Disorder (September 12, 2013)
• Evaluation of Factors Affecting Treatment Response and Risk Factors for Patients Diagnosed With Non-Psychotic Major Depressive Disorder: A Literature Review (September 12, 2013)
• Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US (September 1, 2013)
• Should the Ovaries be Removed During a Hysterectomy? (July 25, 2013)
• Physicians’ Prescribing Decisions and Associated Outcomes Among Type 2 Diabetes Patients (July 1, 2013)
• Incidence of Chemotherapy Induced Nausea and Vomiting Following Prophylaxis with I.V. 5-HT3-RA Antiemetics with and without Subsequent Oral 5-HT3-RAs (June 27, 2013)
• A Comparison of Annual Healthcare Costs and Utilization between Adult Patients with Long and Short Acting Antiepileptic Monotherapy (June 24, 2013)
• Real-World Treatment Patterns in Cushing's Disease Patients in Two Large US Nationwide Databases: Application of a Novel, Graphical Methodology (June 17, 2013)
• Annual Economic Burden Associated with Cushing's Disease in the United States (June 17, 2013)
• Incidence of Cushing's Disease in the United States (June 15, 2013)
• Clinical Outcomes Associated With Rates of Sulfonylurea Use Among Physicians (June 1, 2013)
• Impact of a Multi-Gene Prognostic Assay on Post-Operative Management of Early Stage Non-Small Cell Lung Cancer (May 20, 2013)
• Annual Healthcare Costs and Utilization in Adults Taking Long or Short Acting Antiepileptic Monotherapy (May 20, 2013)
• Oral Antidiabetic Use Among Nursing Home Residents With Diabetes and Moderate to Severe Chronic Kidney Disease (May 18, 2013)
• Patient Characteristics, Antidiabetic Medication Use, and Glycemic Control in Diabetic Nursing Home Residents With Moderate to Severe Chronic Kidney Disease (May 18, 2013)
• Health Care Expenditures Associated With Cancer Patients (May 18, 2013)
• Annual Healthcare Utilization and Costs in Cushing's Disease Patients in the United States (May 18, 2013)
• Evaluation of Polypharmacy in Patients With Type 2 Diabetes Mellitus and Its Association With Medication Adherence and Health Care Costs (May 18, 2013)
• Assessment of Total Healthcare Costs Associated with Selected Comorbidities among Patients with Type II Diabetes Mellitus in a Commercially-Insured U.S. Population (May 18, 2013)
• Association of Severe Hypoglycemic Events and Hospital Readmission With Treatment Non-Concordance to Guidelines and Prescribing Information in Hospitalized Patients With Type-2 Diabetes and Stage 3-5 Chronic Kidney Disease (May 18, 2013)
• Health Care Costs and Clinical Outcomes Associated With Rates of Sulfonylurea Use by Physicians (May 18, 2013)
• Cost-Effectiveness of Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Compared with Efavirenz/Emtricitabine/Tenofovir as First-Line HIV Antiretroviral Therapy in the US Adult Population (May 18, 2013)
• Exploring psychosocial pathways between neighbourhood characteristics and stroke in older adults: the cardiovascular health study (May 1, 2013)
• A Systematic Review of the Impact of Molecular Diagnostics on Treatment Decisions for Patients with Breast Cancer (May 1, 2013)
• Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis (April 4, 2013)
• Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors: Consensus Results From a Modified Delphi Process (April 1, 2013)
• Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses’ Health Study (April 1, 2013)
• Outcomes associated with concordance of oral antidiabetic drug treatments to prescribing information in patients with type 2 diabetes mellitus and chronic kidney disease (February 28, 2013)
• Optimal Interval for Routine Cytologic Screening in the United States (February 11, 2013)
• Neighborhood socioeconomic disadvantage and mortality after stroke (February 5, 2013)
• Severe hypoglycemic events associated with non-guideline-concordant oral anti-diabetic drug treatments in patients with type 2 diabetes and moderate to severe chronic kidney disease: findings from a U.S. commercially-insured population (December 2, 2012)
• Association of severe hypoglycemic risk with package insert recommended renal dose adjustments for oral anti-diabetic drug treatments among commercially insured patients with type 2 diabetes (December 2, 2012)
• Health and Economic Impact of Human Papillomavirus 16 and 18 Vaccination of Preadolescent Girls and Cervical Cancer Screening of Adult Women in Peru (December 1, 2012)
• Use of the 5-HT3-RA Antiemetics in the Prevention and Treatment of Radiation Induced Nausea and Vomiting (November 3, 2012)
• Examining the Use of Rescue Antiemetic Medication for Chemotherapy Induced Nausea and Vomiting in a Commercial Population (November 3, 2012)
• Hematologic Complications, Healthcare Utilization, and Costs in Commercially Insured Patients with Myelodysplastic Syndrome Receiving Supportive Care (November 1, 2012)
• Overall and Disease-Related Healthcare Utilization and Costs in Children with Stable and Uncontrolled Epilepsy (November 1, 2012)
• Medical Treatment Consensus in Unresectable Midgut Gastrointestinal Neuroendocrine Tumors (October 11, 2012)
• Expert Panel Consensus Statements on the Medical Treatment of Unresectable Pancreatic Neuroendocrine Tumors (October 11, 2012)
• Expert Panel Consensus Statements on the Medical Treatment of Unresectable Pancreatic Neuroendocrine Tumors (October 11, 2012)
• Health care claims analysis to quantify the burden of moderate-to-severe asthma (September 1, 2012)
• Hospital Reimbursement Price Cap for Cancer Drugs: The French Experience in Controlling Hospital Drug Expenditures (July 1, 2012)
• Occurrence of Hematologic Conditions in Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents or Supportive Care (June 28, 2012)
• Prevalence of Complications and Treatment in Acromegaly Patients in the United States (June 23, 2012)
• Healthcare Utilization and Costs in Acromegaly Patients in the United States (June 23, 2012)
• Using the Modified RAND/UCLA Delphi Process to Produce Medical Treatment Consensus in Unresectable Midgut Gastrointestinal Neuroendocrine Tumors (June 6, 2012)
• A Comparison of Annual Overall and Epilepsy-related Healthcare Costs Between Adult Patients with Differentially-controlled Epilepsy (June 5, 2012)
• Annual Overall and Epilepsy-related Healthcare Utilization in Adult Epilepsy Patients in the United States (June 5, 2012)
• Patterns of Care in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents (June 2, 2012)
• Using a Novel, Graphical Method to Analyze Complex Treatment Patterns for Patients with Acromegaly (June 2, 2012)
• An Expert Panel Consensus on Medical Treatment of Non-Midgut Unresectable Neuroendocrine Tumors (June 2, 2012)
• Medical Treatment Consensus in Unresectable Midgut Gastrointestinal Neuroendocrine Tumors (June 1, 2012)
• Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa (June 1, 2012)
• The Cost-effectiveness of Improving Cancer Screening Compliance (June 1, 2012)
• The translation and cultural adaptation of the Child Behavior Checklist for use in Israel (Hebrew), Korea, the US (Spanish), India (Malayalam and Kannada), and Spain (May 30, 2012)
• Neighborhood Socioeconomic Disadvantage and Walking: the Cardiovascular Health Study (May 3, 2012)
• New Bundled World: Quality of Care and Readmission in Diabetes Patients (May 1, 2012)
• Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway (April 24, 2012)
• Clinical and economic impact of adhesiolysis during repeat cesarean delivery (March 9, 2012)
• Oral Corticosteroid Use Increases the Risk of Glucocorticoid-Related Adverse Events in Asthmatics (March 4, 2012)
• Cost, Utilization, and Patterns of Medication Use Associated with Chronic Idiopathic Urticaria (February 1, 2012)
• Effect of Oncotype® DX Colon Cancer Test Results on Treatment Recommendations in Patients with Stage II Colon Cancer (January 19, 2012)
• Targeted Therapies for Metastatic Colorectal Cancer: A Systematic Review of Cost Effectiveness (January 19, 2012)
• Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand (January 1, 2012)
• Preoperative Predictors of Weight Loss Following Bariatric Surgery: Systematic Review (January 1, 2012)
• Using Administrative Claims Data to Estimate Virologic Failure Rates among Human Immunodeficiency Virus-infected Patients with Antiretroviral Regimen Switches (January 1, 2012)
• A descriptive analysis of drug treatment patterns and burden of illness for pediatric patients diagnosed with partial-onset seizures in the USA (December 6, 2011)
• The impact of epilepsy on children and adult patients’ lives: Development of a conceptual model from qualitative literature (December 1, 2011)
• Neighborhood Disadvantage and Ischemic Stroke: The Cardiovascular Health Study (CHS) (December 1, 2011)
• Concomitant Asthma Medication Use by Patients Receiving Omalizumab 2003–2008 (December 1, 2011)
• Bayesian Calibration of a Cervical Cancer Model Using Markov Chain Monte Carlo (November 5, 2011)
• Incidence and Cost of Treatment-Emergent Comorbid Events in an Insured Population Receiving Treatment for Chronic Hepatitis C (CHC) Virus Infection (November 5, 2011)
• Systematic Review of Skeletal-Related Events in Prostate Cancer (November 5, 2011)
• Systematic Review of Skeletal-Related Events in Breast Cancer (November 5, 2011)
• Characteristics Associated with Medication Adherence Among New Omalizumab Users (November 3, 2011)
• Association Between Second-Generation Antipsychotic Medication Half-Life and Hospitalization in the Community Treatment of Adult Schizophrenia (October 28, 2011)
• A comprehensive review of the literature on epilepsy in selected countries in emerging markets (September 28, 2011)
• Causes and consequences of injuries in children in Western Australia (September 7, 2011)
• An International Response to Questions about Terminologies, Investigation, and Management of Abnormal Uterine Bleeding: Use of an Electronic Audience Response System (September 1, 2011)
• FIGO - Sistema di classificazione (PALM-COEIN) delle cause di sanguinamento uterino anomalo in donne non gravide e in età riproduttiva (Eng: FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age) (September 1, 2011)
• The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding (September 1, 2011)
• A Five-Year International Review Process Concerning Terminologies, Definitions, and Related Issues around Abnormal Uterine Bleeding (September 1, 2011)
• Does Pay for Performance Improve Cardiovascular Care in a “Real-World” Setting? (September 1, 2011)
• Using Breast Cancer Quality Indicators in a Vulnerable Population (August 1, 2011)
• Methods for Improving Efficiency in Quality Measurement: the Example of Pain Screening (July 18, 2011)
• Cost Effectiveness of Donepezil 23 mg in the Treatment of Moderate to Severe Alzheimer's Disease from a US Payor Perspective (July 16, 2011)
• Does Race/Ethnicity Affect Aging Anxiety in American Baby Boomers? (July 1, 2011)
• Cost-Effectiveness of 21-Gene Assay in Node-Positive, Early-Stage Breast Cancer (July 1, 2011)
• Heart failure patients receiving ACEIs/ARBs were less likely to be hospitalized or to use emergency care in the following year (July 1, 2011)
• Retrospective drug utilization review: impact of pharmacist interventions on physician prescribing (June 24, 2011)
• Healthcare Costs Related to Chemotherapy Induced Nausea and Vomiting: A Retrospective Analysis in a U.S. Commercially Insured Population (June 23, 2011)
• Chemotherapy-Induced Nausea and Vomiting Following Prophylactic 5-HT3-RA Antiemetic Treatment in Highly Emetogenic Chemotherapy (June 23, 2011)
• Chemotherapy-Induced Nausea and Vomiting Following Prophylactic 5-HT3-RA Antiemetic Treatment in Moderately Emetogenic Chemotherapy (June 23, 2011)
• Utilization and healthcare charges in an insured US cystic fibrosis (CF) patient population (June 8, 2011)
• Relationship between Age and Healthcare Utilization in Patients with Myelodysplastic Syndrome Receiving Supportive Care (June 3, 2011)
• Healthcare Costs and Utilization of Insured Patients with Myelodysplastic Syndrome (June 3, 2011)
• HIV Screening in Commercially Insured Patients Screened or Diagnosed With Sexually Transmitted Diseases or Blood-Borne Pathogens (June 1, 2011)
• Race and Gender Associations Between Obesity and Nine Health-Related Quality-Of-Life Measures (June 1, 2011)
• Budget Impact Analysis of Increasing LMWH/FXI Utilization (May 21, 2011)
• The Impact of Epilepsy on Adult and Paediatric Patient’s Lives: A Conceptual Model (May 21, 2011)
• Burden of Illness in the US for Adult Epilepsy Patients with Partial Onset Seizures Receiving Anti-Epileptic Drugs (May 21, 2011)
• Burden of Illness in the US for Pediatric Epilepsy Patients with Partial Onset Seizures Receiving Anti-Epileptic Drugs (May 21, 2011)
• Estimating Severity of Gastroesophageal Reflux Disease (GERD) Using Administrative Claims Data (May 7, 2011)
• Clinical and economic impact of adhesiolysis during repeat cesarean delivery (May 2, 2011)
• Examining Healthcare Costs in Chemotherapy Induced Nausea and Vomiting: A Retrospective Analysis (April 27, 2011)
• Impact of Alvimopan (Entereg) on Hospital Cost After Bowel Resection: Results from a Large In-patient Database (April 1, 2011)
• Treatment Patterns of Patients with Chronic Idiopathic Urticaria (March 18, 2011)
• Concomitant Asthma Medication Use in Patients Treated with Omalizumab (March 18, 2011)
• Physician Survey of the Effect of the 21-Gene Recurrence Score Assay Results on Treatment Recommendations for Patients With Lymph Node–Positive, Estrogen Receptor–Positive Breast Cancer (March 1, 2011)
• FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age (February 22, 2011)
• Adherence to Pulmozyme Treatment among Commercially Insured Patients with Cystic Fibrosis (February 11, 2011)
• Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States (February 2, 2011)
• Is social support associated with greater weight loss after bariatric surgery?: a systematic review (February 1, 2011)
• Progress Report: Using the Delphi Method to Develop a Classification System for Uterine Fibroids (November 21, 2010)
• Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies (November 12, 2010)
• Cost effectiveness of atazanavir-ritonavir vs. lopinavir-ritonavir in HIV-infected patients initiating first-line antiretroviral therapy (November 7, 2010)
• Cost-effectiveness of human papillomavirus vaccination and screening in Spain (November 1, 2010)
• Care of Asthma Patients in Relation to Guidelines (November 1, 2010)
• The Importance of Prevalence on Setting Positive Test Thresholds and on Test Outcomes: The Case of Tuberculosis (October 27, 2010)
• Complications and Costs Associated with Adhesiolysis at the Time of Repeat Cesarean Delivery (October 26, 2010)
• The Effect of Atypical Antipsychotic Half-life on Hospitalization in the Community Treatment of Adult Schizophrenia (October 14, 2010)
• Sensitivity of Atypical Antipsychotics to Partial Adherence: Analysis of a Medicaid Population (October 14, 2010)
• The Impact of Alvimopan on Hospital Cost After Bowel Resection: Results From a Large Inpatient Database (October 3, 2010)
• Improving breast cancer quality of care with the use of patient navigators (October 1, 2010)
• Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China (September 1, 2010)
• Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States (July 8, 2010)
• Neighborhood Disadvantage and Stroke (June 23, 2010)
• Effect of 21-Gene Recurrence Score Results on Treatment Recommendations in Patients Ages 65 and Older with Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer (June 4, 2010)
• Development and Validation of a Model to Predict Virologic Failure Using Administrative Claims (May 15, 2010)
• Construct Validity of the Benign Prostatic Hyperplasia Impact Index (May 15, 2010)
• Treatment Patterns, Resource Utilization and Costs of Patients With Pulmonary Arterial Hypertension in the US (May 15, 2010)
• Exercise Following Bariatric Surgery: Systematic Review (May 1, 2010)
• Bias Associated with Failing to Incorporate Dependence on Event History in Markov Models (April 16, 2010)
• Ratio of Controller to Total Asthma Medications: Determinants of the Measure (March 1, 2010)
• The Importance of Prevalence on Test Thresholds & Outcomes: A Tuberculosis Testing Model (January 1, 2010)
• Poor Disease Control Among Insured Users of High-dose Combination Therapy for Asthma (January 1, 2010)
• Effect of a 21-Gene Reverse-Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations for Patients with Lymph Node–Positive and Estrogen Receptor–Positive Breast Cancer (December 9, 2009)
• Do Sedentary Older Adults Benefit From Community-Based Exercise? Results From the Active Start Program (December 1, 2009)
• Effects of Tadalafil on Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension (October 24, 2009)
• Literature Review and Product Label Claim Review of PRO Measures for Benign Prostatic Hyperplasia (October 24, 2009)
• Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States (October 20, 2009)
• Development of an Evidence-Based Classification System for Uterine Fibroids (October 17, 2009)
• Results From the Healthy Moves for Aging Well Program: Changes of the Health Outcomes (October 12, 2009)
• Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension (October 1, 2009)
• Exploring Alternative Approaches to Routine Outpatient Pain Screening (October 1, 2009)
• Effects of Categorizing Continuous Variables in Decision-Analytic Models (October 1, 2009)
• Effects of tadalafil on health-related quality of life in patients with pulmonary arterial hypertension (August 29, 2009)
• Appropriateness Criteria for Bariatric Surgery: Beyond the NIH Guidelines (August 1, 2009)
• Utilization of Parenteral Nutrition Following Pancreaticoduodenectomy: Is Routine Jejunostomy Tube Placement Warranted? (July 1, 2009)
• Predictors of Weight Loss Following Bariatric Surgery: A Systematic Review (June 21, 2009)
• Cost and Utilization of COPD and Asthma Among Insured Adults in the US (June 1, 2009)
• Does Improving Quality of Care Save Money? Analysis of Health Care Effectiveness Data and Information Set (HEDIS) Measures (May 16, 2009)
• A Review of Treatment Patterns of Patients with Pulmonary Arterial Hypertension in Three European Countries (May 15, 2009)
• Ovarian Conservation at the Time of Hysterectomy and Long-term Health Outcomes in the Nurses' Health Study (May 1, 2009)
• A cost­-effectiveness analysis of folic acid fortification policy in the United States (April 1, 2009)
• High Unmet Need in Severe Allergic Uncontrolled Asthma Patients: A Divergence Between Observed Practice Patterns and the Newly Revised Asthma Treatment Guidelines (March 13, 2009)
• Ovarian Conservation and Long-Term Health Outcomes in the Nurses' Health Study (March 10, 2009)
• Readmissions Following Pancreaticoduodenectomy for Pancreas Cancer: A Population-Based Appraisal (March 1, 2009)
• Are 12 Nodes Needed to Accurately Stage T1 and T2 Colon Cancers? (March 1, 2009)
• Adherence and Persistence with Omalizumab and Fluticasone/salmeterol Within a Managed Care Population (March 1, 2009)
• Asthma Quality-of-care Measures Using Administrative Data: Identifying the Optimal Denominator (February 1, 2009)
• Review of the Confusion in Current and Historical Terminology and Definitions for Disturbances of Menstrual Bleeding (December 1, 2008)
• Waste in the U.S. Health Care System: A Conceptual Framework (December 1, 2008)
• Pregnancy and Fertility Following Bariatric Surgery: A Systematic Review (November 19, 2008)
• What is the Quality of Surgery-Related Information on the Internet? Lessons Learned from a Standardized Evaluation of 10 Common Operations (October 1, 2008)
• Trade-offs in Cervical Cancer Prevention: Balancing Benefits and Risks (September 22, 2008)
• Improvement in Patient-reported Outcomes in a Rituximab Trial in Patients with Severe Rheumatoid Arthritis Refractory to Anti-tumor Necrosis Factor Therapy (June 15, 2008)
• Evaluation of Acetaminophen Exposures Reported to a Regional Poison Control Center for Adult Patients (May 3, 2008)
• Clinical Outcomes and Resource Utilization Associated With Laparoscopic and Open Colectomy Using a Large National Database (May 1, 2008)
• Assessment of Healthcare Utilization Associated with Integrated Healthcare Association's Pay For Performance (P4P) Asthma Measure, Appropriate Use of Rescue Inhalers (March 14, 2008)
• Assessment of Healthcare Utilization Associated with the Health Employer Data and Information Set (HEDIS) Measure, Use of Appropriate Medications for People with Asthma (March 14, 2008)
• Economic Burden in Direct Costs of Concomitant Chronic Obstructive Pulmonary Disease and Asthma in a Medicare Advantage Population (March 1, 2008)
• Abnormal Uterine Bleeding During the Reproductive Years—Terminology and Treatment (January 1, 2008)
• Using Microsimulation Modeling to Capture Heterogeneity in Lifetime Illicit Drug Use (January 1, 2008)
• How Much Do Standardized Forms Improve the Documentation of Quality of Care? (November 1, 2007)
• Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination (October 29, 2007)
• Healthcare cost and utilization associated with comorbid COPD and asthma in the United States (October 20, 2007)
• The burden of comorbid COPD and asthma in a Medicare population (October 20, 2007)
• Retrospective Drug Utilization Review: Impact of Pharmacist Interventions on Physician Prescribing (October 20, 2007)
• An Assessment of the Use of Adhesion Prevention Therapy in a Real-World Setting (October 13, 2007)
• Healthcare utilisation among insured multiple sclerosis patients in the US from 2005-2006 (October 11, 2007)
• Does resection of pancreas cancer have a palliative effect? Longterm appraisal of readmissions (October 7, 2007)
• Impact of Drug Use and Comorbidities on In-Hospital Falls in Patients with Chronic Kidney Disease (October 1, 2007)
• Elective oophorectomy in the gynecological patient: when is it desirable? (August 1, 2007)
• Embedding quality improvement and patient safety—the UCLA value analysis experience (August 1, 2007)
• The Surgeon’s Role in the Quality of Oncologic Care (July 1, 2007)
• Health Care Utilization Over 2000-2005 Among Insured Patients With MS (May 30, 2007)
• Evaluation of Causes and Consequences of Injuries in Children (May 19, 2007)
• Elective oophorectomy for benign gynecological disorders (May 1, 2007)
• Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? (March 1, 2007)
• A Process Designed to Lead to International Agreement on Terminologies and Definitions Used to Describe Abnormalities of Menstrual Bleeding (March 1, 2007)
• Do Standardized Templates Improve Documentation of Quality of Care? (February 6, 2007)
• An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe (January 1, 2007)
• Isterectomia senza ovariectomia: quando è opportuno lasciare a una donna le sole ovaie? (December 1, 2006)
• Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection (December 1, 2006)
• Population-Level Changes in Folate Intake by Age, Gender, and Race/Ethnicity after Folic Acid Fortification (November 1, 2006)
• Response to commentaries on retention of the ovaries and long-term survival after hysterectomy (October 1, 2006)
• The Effect of Medication Adherence on Health Care Utilization in Bipolar Disorder (September 1, 2006)
• Cost-Effectiveness of Treatments for Dysfunctional Uterine Bleeding (July 1, 2006)
• Grand Rounds: Hysterectomy Sans Oophorectomy: The Case for Leaving a Woman's Ovaries Alone (July 1, 2006)
• Association Between In-Hospital Falls, Comorbidities, and Drug Use in Adult Chronic Kidney Disease Patients: A Case-Control Study (May 20, 2006)
• Poor Symptom Control Among Moderate-to-Severe Asthma Patients (April 5, 2006)
• A Method for Classifying Biologics for Formulary Decision Making (April 1, 2006)
• Association Between In-Hospital Falls in Adults and Chronic Diseases, Drug Use, and Anemia: A Matched Case-Control Study (March 17, 2006)
• The impact of first-line biologic choice on pharmacy budget (March 3, 2006)
• Children’s acetaminophen exposures reported to a regional poison control center (February 15, 2006)
• An Evaluation of the Factors Associated with Statin Dose Management and Low-Density Lipoprotein-Cholesterol Goal Attainment (January 1, 2006)
• Treatment Patterns for Women with New Episodes of Uterine Myomas in an Insured Population in the US (January 1, 2006)
• Utilization and Medical Care Expenditures in Patients with Chronic Obstructive Pulmonary Disease: A Managed Care Claims Data Analysis (December 1, 2005)
• Self-Control and Social Bonds: A Combined Control Perspective on Juvenile Offending (December 1, 2005)
• Problem Areas in Diabetes & Fear of Self-Injection: A Comparison of Insulin Delivery Systems (October 19, 2005)
• Insulin treatment satisfaction and fear of self-injection: a comparison of the InnoLet insulin doser and standard vial/syringe (September 12, 2005)
• Gastrointestinal Bleeding Rates among Managed Care Patients Newly Started on COX-2 Inhibitors or Nonselective NSAIDs (September 1, 2005)
• Analysis of Incremental Cost-Effectiveness of ThermaChoice Vs. Novasure for Menorrhagia (September 1, 2005)
• Paediatric Severe Community-Acquired Pneumonia in India (September 1, 2005)
• Reactivation of Latent Granulomatous Infections by Infliximab (August 1, 2005)
• Ovarian Conservation at the Time of Hysterectomy for Benign Disease (August 1, 2005)
• NSAID utilization patterns following market withdrawal of rofecoxib (July 1, 2005)
• Does the Collaborative Model Improve Care for Chronic Heart Failure? (July 1, 2005)
• Comparison of Costs and Utilization Between Users of Insulin Lispro Versus Users of Regular Insulin in a Managed Care Setting (June 1, 2005)
• Measures of Surgical Quality: What will Patients Know by 2005? (June 1, 2005)
• Prevalance and Cost of Bipolar Disorder and Treatment Within a Managed Care Organization (May 15, 2005)
• Impact of Anemia on In-Hospital Falls: A Matched Case-Control Study (May 15, 2005)
• Does Anemia Contribute to Longer Length of Stay in Patients with In-Hospital Falls? (May 15, 2005)
• Impact of an Educational Program on Antibiotic Use in Paediatric Appendectomy Procedures (March 1, 2005)
• Mechanisms of Differential Immunogenicity of Tumor Necrosis Factor Inhibitors (March 1, 2005)
• The Cost of Blood: Multidisciplinary Consensus Conference for a Standard Methodology (January 1, 2005)
• Evaluating the U.S. Folic Acid Fortification Policy: Did We Succeed? (January 1, 2005)
• Evaluation of Monotherapy and Combination Antibiotic Treatment Regimens for Pseudomonas Aeruginosa Pneumonia (October 24, 2004)
• Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction (October 15, 2004)
• Self-Control and Social Bonds: A Combined Control Perspective on Deviance (October 1, 2004)
• Mechanisms of Action of Tumor Necrosis Factor Antagonists and Granulomatous Infections (October 1, 2004)
• Costs of Lower-Extremity Ulcers Among Patients With Diabetes (September 1, 2004)
• Determining the Appropriateness of Selected Surgical and Medical Management Options in Recurrent Stroke Prevention: A Guideline for Primary Care Physicians from the National Stroke Association Work Group on Recurrent Stroke Prevention (September 1, 2004)
• Report From the First Multidisciplinary Cost of Blood Consensus (COBCON) Working Group to Establish Standard Methodology (May 16, 2004)
• Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists (May 1, 2004)
• The Costs of Non-Adherence to Oral Antihyperglycemic Medication in Individuals with Diabetes Mellitus and Concomitant Diabetes Mellitus and Cardiovascular Disease in a Managed Care Environment (March 1, 2004)
• Surgical Quality: Review of Californian Measures (January 17, 2004)
• Economic Impact of Patient Adherence with Antidepressant Therapy Within a Managed Care Organization (December 1, 2003)
• The Benefits and Risks of Folic Acid Fortification (September 1, 2003)
• Liquid medication dosing errors: a pre–post time series in India (June 1, 2003)
• Postpartum Length of Stay and Newborn Health: A Cost-Effectiveness Analysis (April 1, 2003)
• Medical and mental health services utilization among requalified and former drug addiction and alcoholism recipients of SSI (March 1, 2003)
• Drug use prevalence among former SSI DA&A recipients (March 1, 2003)
• Improving Treatment Outcomes with a Clinical Pathway for Hysterectomy and Myomectomy (December 1, 2002)
• Comparison of Long-Term Outcomes of Myomectomy and Uterine Artery Embolization (November 1, 2002)
• Oral Isotretinoin: An Analysis of Its Utilization in a Managed Care Organization (July 1, 2002)
• The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies (June 1, 2002)
• Treatment Patterns of Care and the Risk of Subsequent Fractures Among Osteoporotic Women With Incident Fractures (May 19, 2002)
• Cardiorenal Effects and Costs of COX-2 Inhibitors in a Managed Care Organization (May 19, 2002)
• Patient Adherence with HMG Reductase Inhibitor Therapy among Users of Two Types of Prescription Services (May 1, 2002)
• Adherence to Oral Antidiabetic Therapy in a Managed Care Organization: A Comparison of Monotherapy, Combination Therapy, and Fixed-Dose Combination Therapy (March 1, 2002)
• A Retrospective Analysis of the Relationship Between Changes in Glycemic Control and Health Care Resources Utilized in a Naturalistic Setting (January 1, 2002)
• A retrospective analysis of short-term costs and utilization associated with glycemic control among patients diagnosed with type 2 diabetes within a managed care organization (January 1, 2002)
• Assessing Symptoms Before Hysterectomy: Is the Medical Record Accurate? (July 1, 2001)
• Health Information on the Internet Accessibility, Quality, and Readability in English and Spanish (May 23, 2001)
• Proceed with Caution: a Report on the Quality of Health Information on the Internet (May 1, 2001)
• Motivating High-Risk Older Adults to Exercise: Does Coaching Matter? (April 1, 2001)
• Alignment With The Revised NHLBI 2007 Asthma Guidelines, Expert Panel Report 3 (EPR 3) In A Large Payer Database (March 13, 2001)
• A self-administered instrument for assessing therapeutic approaches of drug-user treatment counselors (February 1, 2001)
• Outpatient Care: A Conceptual Framework And A Form For Structured Implicit Review (January 1, 2001)
• Do Longer Postpartum Stays Reduce Newborn Readmissions? Analysis Using Instrumental Variables (December 1, 2000)
• Program Factors and Treatment Outcomes in Drug Dependence Treatment: An Examination Using Meta-Analysis (October 1, 2000)
• Infant Mortality and Early Postpartum Discharge (August 1, 2000)
• The Active Management of Labor: Is it Worth the Cost? (April 1, 2000)
• An Agenda for Research into Uterine Artery Embolization: Results of an Expert Panel Conference (April 1, 2000)
• The Appropriateness of Recommendations for Hysterectomy (February 1, 2000)
• Uterine Artery Embolization: A Systematic Review of the Literature and Proposal for Research (January 1, 1999)